Immunocore presents Kimmtrak data showing doubled five-year survival rate in metastatic uveal melanoma

Bitget2026/11/06 14:19

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immunocore reported KIMMTRAK net sales of $325 million for January-September 2026, up 10% year over year.
The Phase 3 TEBE-AM cutaneous melanoma trial completed target enrollment of 540 patients; topline data are expected in second-quarter 2027.
KIMMTRAK combined with brenetafusp produced a 29% response rate in 17 previously untreated metastatic uveal melanoma patients.
Overall survival rates for the combination reached 88% at one year and 70% at two years.
A randomized Phase 2/3 DUET-UVEAL trial is planned to evaluate the combination in metastatic uveal melanoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immunocore presents Kimmtrak data showing doubled five-year survival rate in metastatic uveal melanoma

You may also like

Crypto prices